Acute toxicity of a single dose DATR,recombinant soluble human TRAIL mutant,in rodents and crab-eating macaques

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been reported to possess activity of inducing apoptosis in variety of tumor cells in preclinical models. Several mutational versions of TRAIL have been studied as promising agents for cancer therapy and the recombinant soluble human TRAIL mutant (DATR) is one of them. The objective of the present study was to provide possible toxic target organs and proposal non-toxic dose level of DATR for clinical usage. Rodents and crab-eating macaques were used to estimate potential adverse effects of DATR following a single dose administration. The median lethal dose (LD₅₀ ) of intravenous injection to rats and mice was determined as 262.0 and 1018.0 mg/kg b.w., respectively. The LD₅₀ of intraperitoneal administration to mice was found to be 1432.1 mg/kg b.w. The main changes in macaques were found in the following aspects. Hematology analysis revealed an obvious decrease of red blood cell count (RBC), hemoglobin (HB) and hematocrit (HCT) after injection. Serum biochemical analysis showed an apparent increase of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), blood urea nitrogen (BUN) and creatinine (Crea). Furthermore, inflammatory cell infiltrate in liver and kidney was found by microscope. All the disorders suggested that liver, renal and hematological systems might be the target effectors of toxic effect induced by DATR. Based on the results of this study, the no observed-adverse-effect level (NOAEL) and the lowest observed-adverse-effect level of DATR in macaques are 90.0 and 135.0 mg/kg b.w., respectively.

Keywords

acute toxicity DATR macaques mice rats TRAIL

References

Wiley SR , Schooley K. , Smolak PJ , et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995 ; 3: 673-682.

Pitti RM , Marsters SA , Ruppert S. , et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-12690.

Duiker EW , Mom CH , de Jong S. , et al. The clinical trail of TRAIL. Eur J Cancer 2006; 42: 2233-2240.

Ashkenazi A. , Pai RC , Fong S. , et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.

Chinnaiyan AM , Prasad U. , Shankar S. , et al. Combined efect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy . Proc Nat Acad Sci U S A 2000; 97: 1754-1759.

Walczak H. , Miller RE , Ariail K. , et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.

Jo M. , Kim TH , Seol DW , et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564-567.

Pan G. , Ni J. , Wei YF , et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815-818.

Lawrence D. , Shahrokh Z. , Marsters S. , et al. Diferential hepatocyte toxicity of recombinant Apo2L / TRAIL versions. Nat Med 2001; 7: 383-385.

10.

Bodmer JL , Meier P. , Tschopp J. , et al. Cysteine 230 is essential for the structure and activity of the cytotoxic ligan TRAIL. J Biol Chem 2000 ; 275: 20632-20637.

11.

Koschny R. , Walczak H. , Ganten TM The promise of TRAIL-potential and risks of a novel anticancer therapy. J Molecular Med 2007; 85: 923-935.

12.

Qin J. , Chaturvedi V. , Bonish B. , et al. Avoiding premature apoptosis of normal epidermal cells. Nat Med 2001; 7: 385-386.

13.

Higuchi H. , Bronk SF , Takikawa Y. , et al. The bile acid glycochenodeoxycho1ate induces trail-receptor2/DR5 expression and apoptosis. J Biol Chem 2001 ; 276: 38610-38618.

14.

Higuchi H. , Bronk SF , Taniai M. , et al. Cholestasis increases tumor necrosis factor-related apoptotisinducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAILmediated cytotoxicity. J Pharmacol Exper Ther 2002; 303: 461-467.

15.

Higuchi H. , Yoon JH , Grambihler A. , et al. Bile acids stimulate Cflip phosphorylation enhancing TRAIL-mediated apoptosis. J Biol Chem 2003; 278: 454-461.

16.

Held J. , Schulze-Osthoff K. Potential and caveats of TRAIL in cancer therapy. Drug Resistance Updates 2001; 4: 243-252.

17.

Gura T. How TRAIL kills cancer cell, but not normal cells. Science 1997; 277: 768.

18.

Sheridan JP , Marsters SA , Pitti RM , et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821.

19.

Kelley SK , Harris LA , Xie D. , et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299: 31-38.